INNOVUS PHARMA INC COM USD0.001 (INNV)

0.11
OTC Markets
Prev Close 0.11
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.08 / 0.66
Exchange OTC Markets
Shares Outstanding 150.54B
Market Cap 18.06M
Div & Yield N.A. (N.A)

Latest News

Innovus Pharma Launches AllerVarx, A Clinically Proven Supplement For The Relief Of Allergy Symptoms, In The United States

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and...

Innovus Pharma Signs Exclusive License And Distribution Agreement With Luminarie In Australia, New Zealand And The Philippines For Zestra® For Female Sexual Arousal Disorder And Zestra Glide® For Female Lubrication

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization,...

Innovus Pharma Files Its Product License Application In Canada For The Commercialization Of Vesele® As A Natural Health Product To Help Improve Symptoms Of Sexual Dysfunction

Innovus Pharmaceuticals, Inc. (the "Company" or "Innovus Pharma") (OTCQB Venture Market: INNV) today announced that the Company filed its Product License Application with Health Canada as a Natural Health Product ("NPN") to...

Innovus Pharma Signs Exclusive License And Distribution Agreement With Densmore For Zestra® In France And Belgium For Female Sexual Arousal Disorder

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization,...

Innovus Pharmaceuticals Reports Quarterly Revenue For The First Quarter 2017 Of $2.2 Million

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), today announced first quarter 2017 net revenue of $2.

Innovus Pharma Announces Commercial Partnership To Launch FlutiCare™ Under FDA Approved ANDA No. 207957

Innovus Pharmaceuticals, Inc. (the "Company" or "Innovus Pharma") (OTCQB Venture Market: INNV) and its partner West-Ward Pharmaceuticals International Limited ("WWPIL"), a wholly-owned subsidiary of Hikma Pharmaceuticals...

Innovus Pharmaceuticals To Release First Quarter 2017 Financial Results And Provide Corporate Update On Friday, May 12, 2017

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCQB: INNV), today announced that the Company will release its first quarter 2017 financial results and provide a corporate update on Friday, May 12, 2017, after the close...

Innovus Pharma Launches ProstaGorx™ Product For Prostate Health Through Its Beyond Human® Sales And Marketing Platform In The United States

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care...

Innovus Pharmaceuticals Receives Patent For Its Sensum+® Product In Morocco

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization,...

Innovus Pharma Announces Receipt Of Notification To Commercialize Zestra Glide® In The European Union

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and...

Innovus Pharmaceuticals Announces Receipt Of Notice Of Intention To Grant Sensum+® European Patent

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), today announced that it has received a Notice of Intention to Grant from the European Patent Office ("EPO") to issue a European-wide patent...

Innovus Pharmaceuticals Announces The Cash Redemption Of All Outstanding Convertible Notes

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), today announced the cash redemption of all remaining outstanding convertible notes.

Innovus Pharmaceuticals Announces $3.85 Million Public Offering

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), today announced the pricing of a public offering of 25,666,669 shares of common stock, one-year warrants to purchase up to 25,666,669 shares of...

Innovus Pharma Announces Receipt Of Notification To Commercialize Sensum+® In The European Union

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and...

Innovus Pharmaceuticals Reports Record Annual Revenues For The Full Year 2016 Of $4.8 Million

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), today announced full year 2016 net revenues of $4.

Innovus Pharma Announces Receipt Of Notification To Commercialize Zestra® In The European Union

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and...

Innovus Pharmaceuticals To Release Fourth Quarter And Full Year 2016 Financial Results And Provide Corporate Update On Monday, March 6, 2017

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCQB: INNV), today announced that the Company will release its fourth quarter and full year 2016 financial results and provide a corporate update on Monday, March 6, 2017,...

Innovus Pharma Announces The Approval To Commercialize Zestra® In South Korea Through Its Partner J&H Co. LTD

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and...

Innovus Pharma Expands Its Executive Management Team With The Addition Of Randy Berholtz As Its Executive Vice President, Corporate Development And General Counsel

Innovus Pharma Expands Its Executive Management Team With The Addition Of Randy Berholtz As Its Executive Vice President, Corporate Development And General Counsel

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care...

Innovus Pharma Strengthens Its Respiratory Franchise With The In-Licensing Of Lertal® Tablets, A Clinically Proven Supplement For The Relief Of Allergic Rhinitis Symptoms From NTC For The United States And Canada

Innovus Pharma Strengthens Its Respiratory Franchise With The In-Licensing Of Lertal® Tablets, A Clinically Proven Supplement For The Relief Of Allergic Rhinitis Symptoms From NTC For The United States And Canada

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care...

Innovus Pharma Launches Its Clinically Proven UriVarx™ Product For Bladder Health Through Its Beyond Human® Sales And Marketing Platform In The United States

Innovus Pharma Launches Its Clinically Proven UriVarx™ Product For Bladder Health Through Its Beyond Human® Sales And Marketing Platform In The United States

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care...

Innovus Pharma Signs $2 Million A Year Exclusive License And Distribution Agreement With J&H Co. LTD For Zestra® For Female Sexual Arousal In South Korea

Innovus Pharma Signs $2 Million A Year Exclusive License And Distribution Agreement With J&H Co. LTD For Zestra® For Female Sexual Arousal In South Korea

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and...

Innovus Pharma Launches Zestra® Multi-Dose Form For Female Sexual Arousal In The U.S.

Innovus Pharma Launches Zestra® Multi-Dose Form For Female Sexual Arousal In The U.S.

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer...

Innovus Pharma Reports Record Quarterly Revenues For The Third Quarter Of 2016, Increasing 947% To $1.9 Million, And Record Nine Months Ended September 2016 Revenues, Increasing 463% To $3.1 Million

Innovus Pharma Reports Record Quarterly Revenues For The Third Quarter Of 2016, Increasing 947% To $1.9 Million, And Record Nine Months Ended September 2016 Revenues, Increasing 463% To $3.1 Million

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), today announced a 947% increase in third quarter of 2016 revenues to a record $1.

Innovus Pharma Signs Exclusive License And Distribution Agreement With Elis Pharmaceuticals For Zestra® In Lebanon

Innovus Pharma Signs Exclusive License And Distribution Agreement With Elis Pharmaceuticals For Zestra® In Lebanon

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV) announced today it has entered into its second exclusive license and distribution agreement with Elis Pharmaceuticals, Ltd.

Innovus Pharmaceuticals To Release Third Quarter 2016 Financial Results And Provide Corporate Update On Thursday, November 10, 2016

Innovus Pharmaceuticals To Release Third Quarter 2016 Financial Results And Provide Corporate Update On Thursday, November 10, 2016

Innovus Pharmaceuticals, Inc., ("Innovus Pharma") (OTCQB: INNV), today announced that the Company will release its third quarter 2016 financial results and provide a corporate update on Thursday, November 10, 2016, after...

Innovus Pharma Initiates Pre-Clinical And Clinical Program Evaluating The Safety And Efficacy Of Vesele® With Sildenafil (Viagra®)

Innovus Pharma Initiates Pre-Clinical And Clinical Program Evaluating The Safety And Efficacy Of Vesele® With Sildenafil (Viagra®)

Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's and...

Innovus Pharmaceuticals Licenses Urox® Formulation, A Clinically Proven Product For Overactive Bladder And Urinary Incontinence

Innovus Pharmaceuticals Licenses Urox® Formulation, A Clinically Proven Product For Overactive Bladder And Urinary Incontinence

Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") (OTCQB Venture Market:INNV) an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's...